A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand by unknown
Tantai et al. BMC Health Services Research 2014, 14:170
http://www.biomedcentral.com/1472-6963/14/170RESEARCH ARTICLE Open AccessA cost-utility analysis of drug treatments in
patients with HBeAg-positive chronic hepatitis B
in Thailand
Narisa Tantai1,2,4, Usa Chaikledkaew2,4*, Tawesak Tanwandee3, Pitsaphun Werayingyong4
and Yot Teerawattananon4Abstract
Background: Only lamivudine has been included for patients with chronic hepatitis B (CHB) in the National List of
Essential Drugs (NLED), a pharmaceutical reimbursement list in Thailand. There have also been no economic
evaluation studies of CHB drug treatments conducted in Thailand yet. In order to fill this gap in policy research, the
objective of this study was to compare the cost-utility of each drug therapy (Figure 1) with palliative care in patients
with HBeAg-positive CHB.
Methods: A cost-utility analysis using an economic evaluation model was performed to compare each drug treatment
for HBeAg-positive CHB patients. A Markov model was used to estimate the relevant costs and health outcomes during a
lifetime horizon based on a societal perspective. Direct medical costs, direct non-medical costs, and indirect costs were
included, and health outcomes were denoted in life years (LYs) and quality-adjusted life years (QALYs). The results were
presented as an incremental cost effectiveness ratio (ICER) in Thai baht (THB) per LY or QALY gained. One-way sensitivity
and probabilistic sensitivity analyses were applied to investigate the effects of model parameter uncertainties.
Results: The ICER values of providing generic lamivudine with the addition of tenofovir when drug resistance occurred,
generic lamivudine with the addition of tenofovir based on the road map guideline, and tenofovir monotherapy
were -14,000 (USD -467), -8,000 (USD -267) , and -5,000 (USD -167) THB per QALY gained, respectively. However, when
taking into account all parameter uncertainties in the model, providing generic lamivudine with the addition of tenofovir
when drug resistance occurred (78% and 75%) and tenofovir monotherapy (18% and 24%) would yield higher
probabilities of being cost-effective at the societal willingness to pay thresholds of 100,000 (USD 3,333) and 300,000
(USD 10,000) THB per QALY gained in Thailand, respectively.
Conclusions: Based on the policy recommendations from this study, the Thai government decided to include tenofovir
into the NLED in addition to generic lamivudine which is already on the list. Moreover, the results have shown that the
preferred treatment regimen involves using generic lamivudine as the first-line drug with tenofovir added if drug
resistance occurs in HBeAg-positive CHB patients.
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Approximately 350 million people are chronically infected
with the hepatitis B virus (HBV) [1] and nearly 25% of these
carriers develop serious liver diseases such as chronic hepa-
titis, cirrhosis, and hepatocellular carcinoma (HCC), result-
ing in more than one million deaths every year [1]. Chronic
liver diseases and HCC associated with HBV infections are
two of the most important public health problems in high-
prevalence regions [2]. In particular, most Southeast Asian
countries including Thailand have been classified as high
prevalence areas of HBV [1].
The goal of drug treatments for chronic hepatitis B
(CHB) is to improve quality of life and survival by pre-
venting the disease from developing into cirrhosis, decom-
pensated cirrhosis, end-stage liver disease, HCC, and
death by reducing viral replication to the lowest possible
level and maintaining it over the long-term. Currently, six
CHB medications including both oral (i.e., lamivudine,
adefovir, entecavir and telbivudine) and subcutaneous (i.e.,
conventional interferon and pegylated interferon) dosage
forms have been licensed by the Thai Food and Drug Ad-
ministration (FDA). Additionally, tenofovir – an approved
drug for the treatment of HIV but not CHB – is currently
being prescribed to CHB patients in 300 mg daily doses
due to its high viral efficacy and low resistance rates [3,4].
Previous cost-utility analysis studies of oral CHB medica-
tions revealed that telbivudine [5] or adefovir [6,7] was
more cost-effective when compared with lamivudine. In
addition, most studies performed in the US [8-14],
Australia [15], and Asia [16,17] demonstrated that entecavir
was superior when compared with lamivudine. Another
study by Buti et al. showed that tenofovir was the better
cost-effective treatment when compared with entecavir, tel-
vibudine, and adefovir [13]. Moreover, previous economic
evaluation studies of subcutaneous CHB treatments indi-
cated that interferon was not cost-effective when compared
with lamivudine [18,19] but was more cost-effective when
compared to lamivudine with the addition of adefovir when
drug resistance occurred [20]. The combination of lamivu-
dine and interferon would increase life expectancy and re-
duce the lifetime risk of cirrhosis and carcinoma [21,22].
Furthermore, pegylated interferon was more cost-effective
when compared with lamivudine [21,23,24] or interferon
[7]. Most economic evaluation studies of CHB treatment
were carried out in the US and Europe. However, no study
has ever been performed in Southeast Asian countries, in-
cluding Thailand - a high prevalence area of CHB. In
addition, there has also been no economic evaluation study
of the combination of CHB treatments according to the
current clinical practice guidelines on the management of
CHB drug resistance until now.
When this study was conducted, only lamivudine - but not
other CHB treatments with low rates of drug resistance -
had been included for patients with CHB in the National Listof Essential Drugs (NLED), the pharmaceutical reimburse-
ment list referred to by three health insurance schemes
which are Social Security Scheme (9% of the Thai popula-
tion), Civil Servant Medical Benefit Scheme (11% of the Thai
population) and Universal Coverage Scheme (80% of the
Thai population), as a pharmaceutical benefit scheme in
Thailand. The selection criteria for the inclusion of the
NLED are safety, efficacy as well as cost-effectiveness infor-
mation of drugs. The Subcommittees for Development of
NLED had requested the cost-effectiveness information on
CHB treatments from Health Intervention and Technology
Assessment Program (HITAP), the institution responsible
for appraising a wide range of health technologies including
pharmaceuticals, medical devices, interventions, individual
and community health promotion and prevention inter-
ventions. Therefore, the objective of this study was to
compare the cost-utility of each drug therapy (Figure 1)
with consideration for the management of CHB drug
resistance with palliative care in patients with HBeAg-
positive CHB based on a societal perspective. The results
from this study would be used as the cost-effectiveness
information to assist health policy makers (i.e., the Subcom-
mittees for Development of NLED) to make policy decision
whether which CHB drugs should be included in the NLED.
The inclusion of CHB drugs to the NLED could have an
impact on the reimbursement of CHB drugs for all HBeAg-
positive CHB patients under three health insurance schemes
(i.e., Social Security Scheme, Civil Servant Medical Benefit
Scheme and Universal Coverage Scheme) which accounts
for 100% of Thai population.
In Thailand, palliative care has been a usual care for pa-
tients with CHB, therefore it was used as a comparator in
this study, since CHB-infected individuals usually develop
an acute infection which may or may not result in symp-
toms. Those who do not exhibit symptoms and have never
received hepatitis B screening test may not be aware that
they have CHB until they finally develop serious liver dis-
eases (e.g., chronic hepatitis, cirrhosis, and HCC) which
consequently require palliative care. In addition, the clin-
ical practice guidelines for the diagnosis and management
of HBeAg-positive CHB - detailed in the Thailand Con-
sensus Recommendations for Management of CHB 2009
by the former Liver Society Thailand, now known as the
Thai Association for the Study of the Liver (THASL) - did
not have a recommendation for the most appropriate drug
to use as the standard treatment for CHB patients [25,26].
Methods
A cost-utility analysis using a Markov model was con-
ducted to compare the costs and health outcomes of all
available drug treatments in HBeAg-positive CHB pa-
tients with palliative care; the analysis was performed
using a lifetime horizon with a one-year cycle length
based on a societal perspective. The study population
Intervention Scenario 1st Drug 2nd Drug 3rd Drug
Original LMV Generic
LMV
ADV TNV ETV TVD Original LMV Generic
LMV
ADV TNV
1 - TNV - - - - - - - - - - 
2-3 1 Original LMV - -  or - - - - - -
4-5 1 Generic LMV - -  or - -
6-7 1 ADV        or - - - - - - - -





10-11 1 ETV - -  or - - - - - -
12-13 1 PEG - - - - - - -  or 
14-15 1 PEG - - - - - - or
16-17 1 PEG - - - - -        or - -
18-19 1 PEG - - - - or
20-21 1 PEG - - - - - - - or
22 1 PEG - - - - - - - - -
23-24 2 Original LMV - - - - - - -  or 
25-26 2 Generic LMV - - - - - - -  or 
27-28 2 TVD - -  or - - - - - 
Figure 1 All available interventions compared with palliative care. Scenario 1=Adding the second drug when drug resistance occurred;
Scenario 2= Adding a more potent drug without cross-resistance when the HBV DNA level more than 60 IU/ml at week 24 based on the road
map guideline; LMV=Lamivudine; ADV=Adefovir; ETV=Entecavir; TVD=Telbivudine; PEG=Pegylated interferon.
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positive CHB patients aged at least 30 years old who re-
quired the treatment based on the following criteria: 1)
patients who had detectable serum HBsAg for at least
6 months; 2) patients who had serum ALT levels 1.5 -10
times the upper limit of the normal range for at least
3 months; 3) patients who had a detectable level of
serum hepatitis B viral DNA more than or equal to
20,000 IU/ml; and/or 4) patients who had evidence of
CHB based on liver biopsy results. Ethical approval for
this study was granted by the Institutional Review Board
Committees from Mahidol University.
Since this analysis set out to compare all available CHB
medications for the treatment of HBeAg-positive CHB with
palliative care as a usual care and comparator in Thailand,
both oral (i.e., original lamivudine, generic lamivudine, ade-
fovir, entecavir, telbivudine and tenofovir) and subcutane-
ous dosage forms (i.e., pegylated interferon) were included.
Among all the drugs, only tenofovir showed low drug re-
sistance rates in the treatment of CHB [3,4] while others
demonstrated high drug resistance rates. Therefore, two
scenarios based on the current clinical practice guidelines
on the management of CHB drug resistance were created
for the study. Figure 1 presents all interventions compared
with palliative care.In the first scenario, if patients taking the original
lamivudine, generic lamivudine, adefovir, entecaviror, or
telbivudine encountered drug resistance, a second medi-
cation would be added to the treatment regimen based
on the guidelines (10 interventions). Moreover, for CHB
patients receiving pegylated interferon who failed the
treatment, the second drug would be added in the third
year. Then, a third drug would be added if the patient
encountered drug resistance again (11 interventions).
The second scenario involved adding a more potent
drug without cross-resistance when the HBV DNA level
was more than 60 IU/ml at week 24 based on the road-
map guideline, which applies to only low genetic barrier
drugs (i.e., lamivudine and telbivudine) (6 interventions).
Thus, a total of 28 interventions (i.e., tenofovir mono-
therapy, 21 interventions of the first scenario and 6 in-
terventions of the second scenario) were compared with
palliative care (Figure 1).
Model structure
Figure 2 shows the schematic diagram of the Markov
model showing that all hypothetical patients aged at
least 30 years old who required the treatment would
start at the CHB with HBeAg-positive state. For patients
receiving antiviral drugs, they would proceed to the drug
Figure 2 Schematic diagram of the Markov model.
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level of serum HBV DNA reached levels higher than
60 IU/ml. Patients receiving palliative care or those suc-
cessfully treated with pegylated interferon in the first
year would move to the stable state, while HBeAG-
positive CHB patients – either with or without drug re-
sistance – would also be able to transition to this state if
they developed HBeAg seroconversion. In addition,
patients in the stable state could also reverse to the
CHB with HBeAg-positive state. HBeAg-positive CHB
patients - either with or without drug resistance - and
those in the stable state could progress to the compen-
sated cirrhosis, decompensated cirrhosis, and HCC
states. Patients in either the compensated or decompen-
sated cirrhosis state could reverse to a primary state ex-
cept for those with HCC, who could move to a death
state only. Patients in all states could stay at the same
state and could move to a death state. Both scenarios
had the same model assumptions, which were: 1) the ef-
ficacy of generic lamivudine was the same as that of the
original lamivudine, and 2) each treatment had differ-
ences in the seroconversion and resistance rates.
Transitional probabilities
Table 1 demonstrates all the parameters used in the
model. Due to the limitation of data, especially the clin-
ical efficacy of CHB drugs in Thailand, these parameter
values were obtained from internationally published lit-
erature [27,28]. However, we performed an indirect
comparison meta-analysis of these parameters whichrepresents the highest reliable evidence [29]. The transi-
tional probabilities of clinical efficacy in terms of HBeAg
seroconversion of HBeAg-positive CHB treatment op-
tions were estimated from a systematic review and
meta-analysis using a Bayesian random effects model an-
alyzed by WinBUGS1.4 (Medical Research Council and
Imperial College of Science, Technology and Medicine,
United Kingdom) [30]. All other transitional probabil-
ities were obtained from published articles in Thailand
and other countries [31-44]. In addition, the mortality
rates of Thailand’s general population at each age were
used in the analysis [45]. Time-invariant survival rates
for each drug therapy were applied.
Cost
Costs and health outcomes were estimated over a 70-year
period in order to cover the expected lifetime horizon.
The costs of the CHB state included the costs of antiviral
drugs and laboratory and diagnostic tests, which were pro-
jected over a 70-year time horizon using the Markov
model. For the number of antiviral drug utilization and la-
boratory and diagnostic tests used, these values were esti-
mated based on the suggested recommendations of the
THASL clinical practice guidelines [25,26]. The prices of
antiviral drugs were obtained from the reference prices
published by the Thai Ministry of Public Health’s Drug
and Medical Supply Information Center (DMSIC) [46].
The unit costs of the laboratory and diagnostic tests were
retrieved using the reference prices published by the
Comptroller General’s Department of the Thai Ministry of
Table 1 Input parameters used in economic model
Parameter Distribution Mean SE Reference
Yearly discount rate (%)
Costs and outcomes (range) 3 (0-6) [51]
Transitional probability baseline parameters
Probability of stable to CHB state Beta 0.143 0.0650 [31]
Probability of CHB to stable state Beta 0.056 0.0180 [32]
Probability of CHB to compensated in 1st-10th year Beta 0.054 0.0543 [33]
Probability of CHB to compensated in 11th-20th year Beta 0.134 0.1338 [33]
Probability of CHB to compensated in >20th year Beta 0.329 0.3292 [33]
Probability of CHB to HCC in 1st-5th year Beta 0.000 0.0000 [34]
Probability of CHB to HCC in 6th-10th year Beta 0.006 0.0061 [34]
Probability of CHB to HCC in >10th year Beta 0.008 0.0081 [34]
Probability of CHB to death in 1st-5th year Beta 0.010 0.0102 [34]
Probability of CHB to death in 6th-10th year Beta 0.014 0.0144 [34]
Probability of CHB to death in >10th year Beta 0.025 0.0252 [34]
Probability of compensated to decompensated in 1st-3rd year Normal 0.042 0.0003 [35]
Probability of compensated to decompensated in 4th-5th year Normal 0.094 0.0005 [35]
Probability of compensated to decompensated in >5th year Normal 0.066 0.0003 [35]
Probability of compensated to HCC in 1st-3rd year Normal 0.014 0.0002 [35]
Probability of compensated to in HCC 4th-5th year Normal 0.036 0.0003 [35]
Probability of compensated to HCC in >5th year Normal 0.030 0.0002 [35]
Probability of compensated to death in 1st-3rd year Beta 0.014 0.0135 [35]
Probability of compensated to death in >3rd year Beta 0.046 0.0461 [35]
Probability of decompensated to HCC Beta 0.035 0.0354 [36]
Probability of decompensated to death in 1st year Normal 0.260 0.0004 [37]
Probability of decompensated to death in 2nd year Normal 0.390 0.0005 [37]
Probability of decompensated to death in >2nd year Normal 0.240 0.0003 [37]
Probability of HCC to death in 1st year Beta 0.848 0.0011 [37]
Probability of HCC to death in >1st year Beta 0.920 0.0009 [37]
Transitional probability of treatment parameters
Probability of CHB to compensated Beta 0.006 0.0023 [38]
Probability of CHB to HCC Beta 0.009 0.0045 [39]
Probability of CHB to death Beta 0.002 0.0023 [39]
Probability of compensated to HCC Beta 0.015 0.0034 [40]
Probability of compensated to death Beta 0.007 0.0070 [39]
Probability of decompensated to HCC Beta 0.035 0.0127 [41]
Probability of decompensated to death Beta 0.126 0.0291 [42]
Probability of compensated to CHB Beta 0.478 0.0665 [43]
Probability of HCC to death Beta 0.034 0.0227 [44]
Relative risk of seroconversion of lamivudine Normal 3.519 1.3707 [30]
Relative risk of seroconversion of adefovir Normal 3.028 1.3833 [30]
Relative risk of seroconversion of telbivudine Normal 4.286 1.4054 [30]
Relative risk of seroconversion of entecavir Normal 3.846 1.3833 [30]
Relative risk of seroconversion of pegylated interferon Normal 5.356 1.4987 [30]
Relative risk of seroconversion of tenofovir Normal 4.167 1.6403 [30]
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Table 1 Input parameters used in economic model (Continued)
Probability of delay seroconversion of pegylated interferon Normal 0.410 0.0489 [27]
Probability of lamivudine resistance Beta 0.214 0.0214 [28]
Probability of adefovir resistance Beta 0.066 0.0066 [28]
Probability of telbivudine resistance Beta 0.089 0.0089 [28]
Probability of entecavir resistance Beta 0.002 0.0002 [28]
Probability of tenofovir resistance Beta 0.000 0.0000 [28]
Annual direct medical cost
Cost of generic lamivudine Gamma 1,797 180 [46]
Cost of original lamivudine Gamma 34,871 3,487 [46]
Cost of adefovir Gamma 70,298 7,030 [46]
Cost of telbivudine Gamma 51,504 5,150 [46]
Cost of entecavir Gamma 85,745 8,575 [46]
Cost of tenofovir Gamma 15,559 1,556 [46]
Cost of pegylated interferon Gamma 527,379 52,738 [46]
Cost of treatment of compensated cirrhosis Gamma 81,264 81,264 [48]
Cost of treatment of decompensated cirrhosis Gamma 125,127 125,127 [48]
Cost of treatment of HCC Gamma 153,021 153,021 [48]
Cost of laboratory for screening (i.e., HBeAg, HBeAb) Gamma 650 650 [47]
Cost of laboratory for pre-treatment Gamma 3,350 3,350 [47]
Cost of laboratory for monitoring Gamma 4,200 4,200 [47]
Cost of laboratory monitoring for pegylated interferon Gamma 10,620 10,620 [47]
Cost of laboratory monitor for adefovir Gamma 4,560 4,560 [47]
Cost of laboratory for post-treatment Gamma 4,900 4,900 [47]
Annual direct non-medical cost
Cost of transportation Gamma 571 571 [54]
Cost of food Gamma 210 210 [54]
Annual indirect cost
Cost of time loss due to receiving treatment Gamma 824 824 [49]
Cost of productivity loss of compensated cirrhosis Gamma 48 48 [48,49]
Cost of productivity loss of decompensated cirrhosis Gamma 627 627 [48,49]
Cost of productivity loss of HCC Gamma 1,701 1,701 [48,49]
Utility
Utility weight for CHB Normal 0.68 0.00005 [53]
Utility weight for compensated cirrhosis Normal 0.69 0.00016 [53]
Utility weight for decompensated cirrhosis Normal 0.35 0.00031 [53]
Utility weight for HCC Normal 0.38 0.00026 [53]
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states such as compensated cirrhosis, decompensated
cirrhosis, and HCC were obtained from a published
study based in Thailand [48]. However, the costs of
treatment for adverse drug events were not included
in this study.
Direct non-medical costs (i.e., the costs of transporta-
tion, food, and time loss due to receiving treatment) but
not direct medical costs incurred outside the hospital were
included. All direct non-medical and the number of daysdue to sick leave were obtained from a published study
[48]. As for indirect costs, these also included morbidity
costs and were calculated from the productivity loss due
to sick leave. It should be noted that mortality costs were
excluded. Indirect costs were calculated from the number
of days due to sick leave multiplied by the minimum wage
rate of the Thai population obtained from the Thai Minis-
try of Labor’s Department of Labor Protection and Wel-
fare [49]. All costs were converted and reported in year
2010 values using the consumer price index (CPI) [50]
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due to the time horizon being longer than one year. The
average annual exchange rate of Thai baht (THB) to one
US dollar was 30 THB in 2010 [52]. For international
comparison, costs were converted to international dollars
using the purchasing power parity (PPP) $ exchange rate
of 1 PPP$ (2010) per 17.8 THB [53].
Health outcomes
Health outcomes were denoted in life years (LYs) gained
and quality-adjusted life years (QALYs) gained (i.e., the
multiplication of LYs gained and the utility score) and the
utility or quality of life scores of patients were obtained
from a published study after we performed a systematic re-
view on electronic databases (i.e., Pubmed and Cochrane
databases) [54]. The health outcomes of each intervention
were compared with palliative care. Future outcomes were
also discounted at a rate of 3% [51]. The results were pre-
sented as an incremental cost effectiveness ratio (ICER) in
Thai baht (THB) per a LY or QALY gained.
Uncertainty analysis
A one-way sensitivity analysis and probabilistic sensitiv-
ity analysis (PSA) were conducted to examine the effect
of parameter uncertainty in the model. All parameters in
the one-way sensitivity analysis were varied across the
range of confidence intervals. In addition, net monetary
benefit (NMB) was calculated to determine the interven-
tion which gave the maximum expected NMB for each
value of the ceiling ratio (i.e., the value of society’s will-
ingness to pay (WTP) for an intervention giving one
QALY gained). In Thailand, the WTP per one QALY
thresholds for the implementation of health technology
and intervention based on two subcommittees - the Sub-
committee for the Development of the National List of
Essential Drugs and the Subcommittee for the Develop-
ment of the Benefit Packages, National Health Security
Office (NHSO) - are 100,000 (USD 3,333) and 300,000
(USD 10,000) THB per QALY gained (i.e., about one and
three times the gross domestic product (GDP) per
capita) [55]. Once the analysis was completed, the re-
sults of the PSA were presented using cost-effectiveness
acceptability curves.
Results
The total costs, LYs, QALYs, and ICER values of all treat-
ments compared with palliative care in patients with
HBeAg-positive CHB aged 30 years old and above are
shown in Table 2. Interventions with negative ICER values
indicate that they were more effective and had lower costs
compared with palliative care. Thus, it can be seen that
providing generic lamivudine and adding tenofovir when
drug resistance occurred (ICER = -9,000 THB or USD -300
per LY gained or -14,000 THB or USD -467 per QALYgained) proved to be the most cost-effective option. The
next best treatment regimens were generic lamivudine plus
tenofovir based on the roadmap guideline (ICER = -5,000
THB or USD -167 per LY gained or -8,000 THB or
USD -267 per QALY gained) and tenofovir monother-
apy (ICER = -3,000 THB or USD -100 per LY gained
or -5,000 THB or USD -167 per QALY gained).
Uncertainty analysis
Figure 3 presents a tornado diagram illustrating the one-
way sensitivity analysis results. Only the important pa-
rameters of the most cost-saving intervention were se-
lected (i.e., generic lamivudine with the addition of
tenofovir when drug resistance occurred). The outcome
of this analysis showed which parameters the ICER per
QALY gained were most sensitive to when altering the
values, and they are listed as follows from most to least
sensitive: the cost of treatment of compensated cirrhosis;
the price of tenofovir; the price of lamivudine; the cost
of treatment of decompensated cirrhosis; the cost of
treatment of HCC; the discount rates of 0% and 6% per
annum for cost and outcome; the relative risk of sero-
conversion of lamivudine; and the probability of transi-
tioning from a CHB state to the death state.
The PSA results are presented in Figure 4 using cost-
effectiveness acceptability curves. To clearly present the
results, other treatment alternatives were omitted except
for tenofovir monotherapy, generic lamivudine with the
addition of tenofovir when drug resistance occurred, and
generic lamivudine with the addition of tenofovir based
on the roadmap guideline compared with palliative care.
The willingness to pay (WTP) threshold for one QALY
for the adoption of health technologies and interven-
tions is designated by the dashed vertical lines. At WTP
thresholds of 100,000 (USD 3,333) and 300,000 THB
(USD 10,000) per one QALY gained in Thailand, the
probabilities for cost-effective treatment via the
provision of generic lamivudine with the addition of
tenofovir when drug resistance occurred were 78% and
75%, respectively. Moreover, the probabilities of tenofo-
vir monotherapy being cost-effective were 18% and 24%,
respectively. However, the probability of providing gen-
eric lamivudine with the addition of tenofovir based on
the roadmap guideline being cost-effective was 0%, re-
gardless of how much society was willing to pay for one
QALY gained.
Discussion
With the intent of aiding policy decision makers on
which CHB drugs should be included in the NLED, our
study was the first to compare the cost-utility of each
drug therapy according to the THASL clinical practice
guidelines with palliative care in patients with HBeAg-
positive CHB based on a societal perspective. Even








QALY gainedFirst drug (Second drug) Third drug
1. Generic lamivudine (tenofovir)† 456,000 20.87 13.66 -72,000 5.03 Dominant*
2. Generic lamivudine (tenofovir)‡ 490,000 20.87 13.66 -38,000 5.03 Dominant*
3. Tenofovir monotherapy† 501,000 20.89 13.67 -26,000 5.04 Dominant*
4. Palliative care 527,000 13.13 8.63 - - -
5. Original lamivudine (tenofovir)† 937,000 20.87 13.66 409,000 5.03 81,000
6. Pegylated interferon (original lamivudine) tenofovir† 953,000 20.89 13.67 426,000 5.05 84,000
7. Original lamivudine (tenofovir)‡ 971,000 20.87 13.66 444,000 5.03 88,000
8. Generic lamivudine (adefovir)† 982,000 20.87 13.66 454,000 5.03 90,000
9. Pegylated interferon (tenofovir)† 1,057,000 20.91 13.69 530,000 5.06 105,000
10. Telbivudine (tenofovir)† 1,091,000 20.90 13.68 564,000 5.05 112,000
11. Generic lamivudine (adefovir)‡ 1,134,000 20.87 13.66 606,000 5.03 121,000
12. Telbivudine (tenofovir)‡ 1,134,000 20.87 13.66 606,000 5.03 121,000
13. Pegylated interferon (original lamivudine) tenofovir† 1,325,000 20.89 13.67 798,000 5.05 158,000
14. Adefovir (generic lamivudine)† 1,364,000 20.85 13.64 837,000 5.01 167,000
15. Pegylated interferon (lamivudine) adefovir† 1,371,000 20.89 13.67 844,000 5.05 167,000
16. Telbivudine (adefovir)† 1,429,000 20.90 13.68 902,000 5.05 178,000
17. Pegylated interferon (telbivudine) tenofovir† 1,442,000 20.92 13.69 915,000 5.06 181,000
18. Original lamivudine (adefovir)† 1,463,000 20.87 13.66 936,000 5.03 186,000
19. Entecavir (tenofovir)† 1,519,000 20.88 13.67 991,000 5.04 197,000
20. Entecavir (adefovir)† 1,536,000 20.88 13.67 1,009,000 5.04 200,000
21. Adefovir (original lamivudine)† 1,564,000 20.85 13.64 1,037,000 5.01 207,000
22. Original lamivudine (adefovir)‡ 1,616,000 20.87 13.66 1,088,000 5.03 216,000
23. Pegylated interferon (adefovir) generic lamivudine† 1,648,000 20.88 13.66 1,120,000 5.04 222,000
24. Telbivudine (adefovir)‡ 1,657,000 20.90 13.68 1,130,000 5.05 224,000
25. Pegylated interferon (telbivudine) adefovir† 1,710,000 20.92 13.69 1,182,000 5.06 233,000
26. Pegylated interferon (original lamivudine) adefovir† 1,744,000 20.89 13.67 1,216,000 5.05 241,000
27. Pegylated interferon (entecavir) tenofovir† 1,771,000 20.90 13.68 1,243,000 5.05 246,000
28. Pegylated interferon (entecavir) adefovir† 1,785,000 20.90 13.68 1,257,000 5.05 249,000
29. Pegylated interferon (adefovir) original lamivudine† 1,812,000 20.88 13.66 1,284,000 5.04 255,000
†Scenario 1: Adding drug when drug resistance occurred; ‡Scenario 2: Adding drug based on the road map guideline.
§total costs are calculated in 2010 THB and rounded up to nearest 1,000 THB.
*Negative ICER due to higher effectiveness and lower costs of intervention compared with palliative care.
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http://www.biomedcentral.com/1472-6963/14/170though the ICER results indicated that these three alter-
natives were dominant due to higher effectiveness and
lower costs when compared with palliative care, it is evi-
denced that both tenofovir monotherapy and generic
lamivudine with the addition of tenofovir when drug re-
sistance occurred were more superior than generic lami-
vudine with tenofovir added based on the roadmap
guideline when taking the uncertainty of all parameters
in the model into account. The results have shown that
the total cost of generic lamivudine with tenofovir added
based on the roadmap guideline was higher compared
with generic lamivudine plus tenofovir when drug resist-
ance, whereas total LYs and QALYs obtained from bothinterventions were not different. As a result, when com-
pared with providing generic lamivudine plus tenofovir
added based on the road map guideline providing gen-
eric lamivudine plus tenofovir when drug resistance
could save healthcare costs of approximately 70,000
THB (USD 2,333) per patient due to the cost avoidance
of serious complications in the future. Thus, when con-
sidering the provision of CHB treatment to HBeAg-
positive CHB patients above 30 years of age (i.e., 40-70
years), providing generic lamivudine plus tenofovir when
drug resistance occurred and tenofovir monotherapy
were dominant and cost-saving interventions compared
with palliative care.
Figure 3 Tornado diagram illustrating the one-way sensitivity analysis results.
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http://www.biomedcentral.com/1472-6963/14/170Furthermore, generic lamivudine, which has already
been included in the NLED, should be considered as the
first-line drug for the treatment of HBeAg-positive CHB
patients above 30 years of age (i.e., 40-70 years) who re-
quire the treatment. In contrast to the findings of other
previously published studies, entecavir [8-17], adefovir
[6,7], telbivudine [5], and pegylated interferon [21,23,24]
were more cost-effective compared with lamivudine.
This could be explained by the fact that our study con-
sidered drug resistance due to lamivudine to imitate the
real current clinical practice. Moreover, generic lamivu-
dine, which is very inexpensive in Thailand, was also in-
cluded as one of the interventions.
Although lamivudine can cause HBV DNA suppres-
sion in most HBeAg-positive CHB patients, it is also as-
sociated with a high rate of drug resistance [28]. Our
study indicated that tenofovir, which was a cost-saving
option, should be used as either the first- or second-line
drug for the management of drug resistance due to nu-
cleoside analog such as lamivudine. Similarly, the studyof Buti et al. revealed that tenofovir was associated with
lower costs and higher efficacy than entecavir, telbivu-
dine, and adefovir [13]. At the time of the study, no
other CHB treatments with low rates of drug resistance
(e.g., tenofovir) had been included in the NLED yet, even
though tenofovir demonstrated high antiviral efficacy
and low drug resistance for patients with CHB [3,4].
Therefore, we submitted the cost-effectiveness informa-
tion of CHB treatments along with policy recommenda-
tions to the Subcommittees for Development of NLED
in May 2012 that tenofovir should be included in the
NLED [56]. After the meeting, it was announced that
tenofovir would be included in the NLED only for CHB
patients with drug resistance due to nucleoside analog
such as lamivudine under the condition that tenofovir
should be used as an alternative and not as the first-line
therapy.
However, based on the expert’s opinion, if both lami-
vudine and tenofovir were included in the NLED, using
tenofovir as the first-line drug would be the better
Figure 4 Cost-effectiveness acceptability curves presenting PSA results.
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http://www.biomedcentral.com/1472-6963/14/170option given that tenofovir has a very low resistance rate.
It would be more convenient for clinicians to provide
tenofovir as the first-line treatment in order to reduce
the time and cost of drug resistance management com-
pared with providing lamivudine as the first-line drug.
Even if the patients taking tenofovir developed drug re-
sistance, lamivudine could be added later. It should be
noted though that tenofovir has also been implicated in
causing renal toxicity. Tenofovir can also cause acute
renal failure, Fanconi syndrome, proteinuria or tubular
necrosis. These side effects are due to accumulation of
the drug in proximal tubules [57].
Moreover, three major issues (i.e., the prices of tenofovir
and lamivudine, resistance rate of tenofovir, and costs of all
complications and adverse drug events) need to be ad-
dressed. First, it was noted that the price of tenofovir in this
study was obtained from the current market price of teno-
fovir in Thailand, which is relatively inexpensive due to the
discounted price (43 THB or USD 1.43) proposed by the
pharmaceutical company. At present, the price of tenofovir
is approximately equal to that of entecavir in many coun-
tries. If the maximum expected price of tenofovir was as-
sumed to be equal to the price of entecavir (235 THB or
USD 7.83 per tablet), the ICER value would change from a
dominant value to 100,000 THB (USD 3,333) per QALY
gained when compared with palliative care. Similarly, if the
price of lamivudine was adjusted to the price of original
lamivudine, the ICER would be adjusted to 81,000 THB
(USD 2,700) per QALY gained. Therefore, when changing
the prices to current market prices, tenofovir monotherapy
or lamivudine would still be cost-effective in the Thaicontext although they would not be cost-saving interven-
tions [55].
Second, according to the current studies related to drug
resistance, the resistance rate of tenofovir used in this study
was 0% [28]. If the resistance rate of tenofovir was assumed
to be equal to that of entecavir based on expert opinion, it
would still be a cost-effective intervention in the Thai con-
text with an ICER of 8,000 THB (USD 267) per a QALY
gained compared with palliative care.
Third, the direct medical costs of complication states in
this study were obtained from a published multi-center ob-
servational study of hepatitis C conducted at five major ter-
tiary care hospitals in Thailand [48]. The costs of all
complications (i.e., compensated cirrhosis, decompensated
cirrhosis, and HCC) in patients with hepatitis C might be
lower than those conducted in CHB patients. Based on the
sensitivity analysis results, the costs of all complications
had the greatest effect on the changes in ICER values. It is
suggested that providing generic lamivudine plus tenofovir
when drug resistance occurred and tenofovir monotherapy
would be cost-effective options since the ICER values were
lower than one times the Thai GDP per capita [55]. In
addition, the costs of treatment of the adverse drug events
were not considered in the study. In particularly, generic
lamivudine may result in more adverse drug events or side-
effects. However, it is expected that the adverse drug reac-
tions of generic lamivudine and tenofovir may have little ef-
fect on an increase in the ICER values. Lok et al.’s study
showed that lamivudine treatment had an excellent safety
profile in HBeAg-positive CHB patients [58] and nausea
was the only adverse event that occurred more frequently
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impact on the cost [59].
It is important that the limitations of this study need to
be addressed. Due to the lack of transitional probabilities
data for CHB patients in Thailand, some transitional prob-
abilities were obtained from published articles in other
countries [27,28,31-44]. However, we specifically performed
a meta-analysis which could yield the most reliable evi-
dence [30]. Furthermore, the utility data of CHB has been
gathered but not for all complication states (i.e., compen-
sated cirrhosis, decompensated cirrhosis, and HCC) in Thai
CHB patients; therefore, the utility data of CHB patients
with complications were obtained from a multinational
study [54].
Conclusions
Our results suggested that providing generic lamivudine
with the addition of tenofovir when drug resistance oc-
curred, generic lamivudine with the addition of tenofovir
based on the roadmap concept, and tenofovir monotherapy
were dominant and cost-saving interventions compared
with palliative care. However, when taking into account all
parameter uncertainties in the model, providing generic
lamivudine with the addition of tenofovir when drug resist-
ance occurred and tenofovir monotherapy would yield
higher probabilities of being cost-effective at the societal
WTP thresholds in Thailand compared with other alterna-
tives. According to the cost-effectiveness results obtained
from this study, the Subcommittees for Development of
NLED decided to include tenofovir into the NLED. It is
recommended that generic lamivudine should be used as
the first-line drug and tenofovir should be considered when
drug resistance occurs for HBeAg-positive CHB patients
under the condition that tenofovir should be used as an al-
ternative and not as the first-line therapy. Given that
tenofovir is included in the NLED, a pharmaceutical reim-
bursement list of three health insurance schemes (i.e., So-
cial Security Scheme, Civil Servant Medical Benefit Scheme
and Universal Coverage Scheme) accounting for approxi-
mately 100% of Thai population, the cost of tenofovir in-
curred by all HBeAg-positive CHB patients under these
health insurance schemes could be reimbursed by the Thai
government. Consequently, this could definitely help
HBeAg-positive CHB patients gain more access to tenofovir
when drug resistance occurred and finally could improve
patient outcomes and decrease mortality. However, due to
a lack of information about drug resistance rate of tenofovir,
it is also recommended that intensive monitoring and
evaluation of drug resistance should continue to be per-
formed by the Department of Disease Control and the De-
partment of Medical Sciences.
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